Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H29BrF2O7 |
| Molecular Weight | 559.394 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCC(=O)[C@]1(CC[C@H]2[C@@H]3C[C@@H](F)C4=CC(=O)C(Br)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)OC(C)=O
InChI
InChIKey=YCISZOVUHXIOFY-HKXOFBAYSA-N
InChI=1S/C25H29BrF2O7/c1-12(29)34-11-21(33)24(35-13(2)30)6-5-14-15-7-18(27)16-8-19(31)17(26)9-23(16,4)25(15,28)20(32)10-22(14,24)3/h8-9,14-15,18,20,32H,5-7,10-11H2,1-4H3/t14-,15-,18+,20-,22-,23-,24-,25-/m0/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/3957156Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/341904
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3957156
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/341904
Halopredone (THS-201; (17,21-bis(acetyloxy)-2-bromo-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione; halopredone acetate; Topicon) is a highly topical corticosteroid. When it is used for intraarticular injections, the effects last longer than any other steroids which have been used, and it has less general effects. Halopredone acetate is used for arthritis and osteoarthritis (OA) patients. For RA patients, mean dose for a wrist is 12.5 mg and that for a knee is 25 mg. About 90% cases showed effectiveness and in about 45% cases the duration of effect is longer than 4 weeks. More than half cases of OA showed also improvements. It also possesses positive anti-inflammatory properties in dermatologic patients.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3957156
for rats:
locally: 80 micrograms/pellet
s.c.: 100 mg/kg
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24NUL39JY1
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
m1183
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
C166537
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
57781-14-3
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106520
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
DTXSID30206477
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
91667
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
260-951-4
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
300000055141
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
C015912
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY | |||
|
1354
Created by
admin on Mon Mar 31 19:33:35 GMT 2025 , Edited by admin on Mon Mar 31 19:33:35 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD